Az oldal megfelelő megjelenítéséhez engedélyezze böngészőjében a JavaScript használatát!

You are here

Baráth Barbara

Baráth Barbara

Name: Baráth Barbara

Publication list

printer-friendly version

Export to MTMT compatible RIS file
Upload publications
Request certified publication list

Uploaded publications:

8

Publications in DEA:

8

OA:

4

Date range:

2018-2023

2023

Somodi, L., Horváth, E., Bárdos, H., Baráth, B., Pethő, D., Katona, É., Balla, J., Mutch, N., Muszbek, L.: Cellular FXIII in Human Macrophage-Derived Foam Cells.
Int. J. Mol. Sci. 24 (5), 1-12, 2023.

Journal metrics:

Q2 Catalysis (2021)
Q1 Computer Science Applications (2021)
Q1 Inorganic Chemistry (2021)
Q1 Medicine (miscellaneous) (2021)
Q2 Molecular Biology (2021)
Q1 Organic Chemistry (2021)
Q1 Physical and Theoretical Chemistry (2021)
D1 Spectroscopy (2021)

2022

Székely, E., Orbán-Kálmándi, R., Szegedi, I., Katona, É., Baráth, B., Czuriga-Kovács, K., Lóczi, L., Molnárné Vasas, N., Fekete, I., Fekete, K., Berényi, E., Oláh, L., Csiba, L., Bagoly, Z.: Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis.
Front. Cardiovasc. Med. 9 1-14, 2022.

Journal metrics:

Q1 Cardiology and Cardiovascular Medicine (2021)

2021

Baráth, B., Kissné Bogáti, R., Miklós, T., Kállai, J., Mezei, Z., Bereczky, Z., Muszbek, L., Katona, É.: Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203 110-116, 2021.

Journal metrics:

Q1 Hematology
Bagoly, Z., Baráth, B., Orbán-Kálmándi, R., Szegedi, I., Kissné Bogáti, R., Sarkady, F., Csiba, L., Katona, É.: Incorporation of [alfa]2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Biomolecules. 11 (3), 1-13, 2021.

Journal metrics:

Q2 Biochemistry
Q2 Molecular Biology

2020

Zabczyk, M., Natorska, J., Bagoly, Z., Sarkady, F., Baráth, B., Katona, É., Bryk, A., Zettl, K., Wisniewski, J., Undas, A.: Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
J. Physiol. Pharmacol. 71 (4), 519-524, 2020.

Journal metrics:

Q2 Medicine (miscellaneous)
Q2 Pharmacology
Q2 Physiology
Bryk, A., Siudut, J., Broniatowska, E., Bagoly, Z., Baráth, B., Katona, É., Undas, A.: Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Thromb. Res. 185 88-62, 2020.

Journal metrics:

Q1 Hematology

2018

Baráth, B., Bagoly, Z., Szegedi, I., Orbán-Kálmándi, R., Csiba, L., Katona, É.: Incorporation of Alpha-2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients Receiving Thrombolytic Therapy.
Proceedings. 2 (9), 101-102, 2018.
Bagoly, Z., Baráth, B., Szegedi, I., Orbán-Kálmándi, R., Csiba, L., Katona, É.: The Effect of Factor XIII Levels on the Incorporation of [alfa]2-plasmin Inhibitor into Fibrin Clots: association with the Therapeutic Outcome of Acute Ischemic Stroke Patients.
Res. Pract. Thromb. Haemost. 2 198-198, 2018.

updated: 2023-03-30, 01:22